menu
    • menu
    [{"orgOrder":0,"company":"Invios","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"APN401","moa":"CBLB messenger RNA (CBLB mRNA)","graph1":"Oncology","graph2":"Phase I","graph3":"Invios","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invios \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Invios \/ Undisclosed"},{"orgOrder":0,"company":"Invios","sponsor":"Austrian Research Promotion Agency","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Oligonucleotide","year":"2023","type":"Funding","leadProduct":"APN401","moa":"CBLB messenger RNA (CBLB mRNA)","graph1":"Oncology","graph2":"Phase I","graph3":"Invios","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invios \/ Austrian Research Promotion Agency","highestDevelopmentStatusID":"6","companyTruncated":"Invios \/ Austrian Research Promotion Agency"},{"orgOrder":0,"company":"Invios","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"APN401","moa":"CBLB messenger RNA (CBLB mRNA)","graph1":"Oncology","graph2":"Phase I","graph3":"Invios","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invios \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Invios \/ Undisclosed"},{"orgOrder":0,"company":"Invios","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"APN401","moa":"CBLB messenger RNA (CBLB mRNA)","graph1":"Oncology","graph2":"Phase I","graph3":"Invios","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Invios \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Invios \/ Undisclosed"},{"orgOrder":0,"company":"Invios","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"INV501","moa":"Tumor growth","graph1":"Oncology","graph2":"Preclinical","graph3":"Invios","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Invios \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Invios \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Invios","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"INV501","moa":"Tumor growth","graph1":"Oncology","graph2":"Preclinical","graph3":"Invios","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Invios \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Invios \/ Undisclosed"},{"orgOrder":0,"company":"Invios","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2024","type":"Series A Financing","leadProduct":"INV501","moa":"Tumor growth","graph1":"Oncology","graph2":"Preclinical","graph3":"Invios","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Invios \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Invios \/ Ligand Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Invios

    Menu

    Invios

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Invios

                            Austria arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Invios

                            Austria arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INV501

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Ligand Pharmaceuticals

                            Deal Size : $8.8 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Invios Raises €8.2 Million in a Series A to Finance Pipeline Progress in Immuno-Oncology

                            Details : The net proceeds will secure ongoing pipeline progress, including INV501, a first-in-class orally available small molecule that can selectively enhance T cell mediated anti-tumor immune responses.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 15, 2024

                            Lead Product(s) : INV501

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Ligand Pharmaceuticals

                            Deal Size : $8.8 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Invios

                            Austria arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Invios

                            Austria arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APN401

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PBMC-based Leukocyte Immunotherapy

                            Details : APN401 is a Oligonucleotide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            December 15, 2023

                            Lead Product(s) : APN401

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Invios

                            Austria arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Invios

                            Austria arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INV501

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Dana-Farber Cancer Institute

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            invIOs and Dana-Farber Cancer Institute Start Collaboration to Study Novel Small Molecule INV501 for Treatment...

                            Details : The collaboration aims to evaluate invIOs’ small molecule INV501 that can selectively enhance anti-tumor immune responses, as a potential treatment for glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 09, 2023

                            Lead Product(s) : INV501

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Dana-Farber Cancer Institute

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Invios

                            Austria arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Invios

                            Austria arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APN401

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Austrian Research Promotion Agency

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            invIOs Starts Further Clinical Trial of APN401, Novel Cell Therapy Against Solid Cancers, and Secures Major Au...

                            Details : The funding will be used for a Phase 1b trial of its novel autologous cell therapy, APN401, an innovative approach that leverages invIOs’s proprietary EPiC cell therapy platform, in patients with solid tumors.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            September 06, 2023

                            Lead Product(s) : APN401

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Austrian Research Promotion Agency

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Invios

                            Austria arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Invios

                            Austria arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INV501

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            invIOs Presents Exciting Preclinical Data Showing that Immune-Activating Small Molecule INV501 Induces Strong ...

                            Details : INV501 is a novel oral small molecule candidate that can selectively enhance anti-tumor immune responses. It induces T cell activation, proliferation, and tumor-reactive cytotoxicity.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 19, 2023

                            Lead Product(s) : INV501

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Invios

                            Austria arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Invios

                            Austria arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APN401

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            invIOs To Present Data From Clinical Stage Cbl-b Program At SITC 2022

                            Details : APN401 (siRNA-transfected peripheral blood mononuclear cells) is an Autologous Cell Therapy using siRNA mediated silencing of Cbl-b resulting in highly activated tumor-reactive white blood cells.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            October 18, 2022

                            Lead Product(s) : APN401

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Invios

                            Austria arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Invios

                            Austria arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APN401

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            invIOs Goes Live with Unique Cell Therapy Platform and Clinical-Stage Immuno-Oncology Pipeline

                            Details : The first clinically validated target is the immune master-checkpoint Cbl-b; the clinical-stage lead candidate APN401 will show results in the near term on safety with data from an ongoing Phase 1b trial.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            December 16, 2021

                            Lead Product(s) : APN401

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth